Chronic Proton Pump Inhibitor Use Leading to Refractory Hypomagnesaemia in a Patient with Rheumatoid Arthritis: A Case Report

Authors

  • Rizwanullah
  • Muzamil Khan
  • Radhika Bassi
  • Samah Badr Hamad
  • Reem Eisa
  • Henna Patel

DOI:

https://doi.org/10.53555/jptcp.v31i8.7281

Keywords:

Proton pump inhibitors, PPI-induced hypomagnesaemia, magnesium depletion, prolonged PPI usage, Hayatabad Medical Complex, refractory hypomagnesaemia, intravenous magnesium supplementation

Abstract

The widespread utilization of proton pump inhibitors has surged in recent times, making them one of the most frequently prescribed medications. Magnesium, a crucial intracellular cation, contributes to numerous cellular functions. Depleted magnesium levels can trigger a range of adverse events. The cause of hypomagnesaemia associated with proton pump inhibitors remains uncertain. A 43-year-old female presented Out Patient Department (OPD) of Hayatabad Medical Complex, with a range of symptoms including weakness, anorexia, lethargy, tremor, and muscle fasciculation. She is a diagnosed case of Rheumatoid Arthritis. Following her Rheumatoid Arthritis diagnosis, she commenced prednisone treatment, which induced epigastric pain. Consequently, she initiated proton pump inhibitors usage for a prolonged period of 12 years, leading to PPI-induced hypomagnesaemia. The objective of this study is to avoid unnecessary use of PPIs and if someone use it for chronic condition then Magnesium level should be assessed during that time to avoid any dreadful complication of hypomagnesaemia like arrhythmias.

Author Biographies

  • Rizwanullah

    Department of Medicine, Hayatabad Medical Complex, Pakistan

  • Muzamil Khan

    Department of Medicine, GW School of Medicine and Health Sciences, USA

     

  • Radhika Bassi

    Department of Medicine, Ross University School of Medicine, Barbados

  • Samah Badr Hamad

    Department of Basic Medical Sciences, University of Khartoum, Sudan

  • Reem Eisa

    Department of Medicine, Ain Shams University, Egypt

     

  • Henna Patel

    Department of Medicine, GMERS Hospital, India

References

Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther. 1999; 13 Suppl 3:3-10.

Playford RJ, Podas T, Modlin I. Pantoprazole, Prout and the proton pump. Hosp Med. 1999; 60:500-504.

Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000;40:52-62.

Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101:445-448.

Danziger J, William JH, Scott DJ, et al. Proton pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 2013;83(4):692-699.

Luk CP, Parsons R, Lee YP, et al. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother. 2013;47(6):773-780.

Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25-35.

Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528-534.

Hess MW, de Baaij JH, Broekman MM, et al. Common single nucleotide polymorphisms in transient receptor potential melastatin type 6 increase the risk for proton pump inhibitor-induced hypomagnesemia: a case-control study. Pharmacogenet Genomics. 2017;27:83-88.

Gommers LM, Hoenderop JG, de Baaij JH. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol (Oxf). 2022;235

Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355:1834-1836.

Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors--a review. Neth J Med. 2009;67:169-172.

FDA Drug Safety Communication. Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). Available from: http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm.

Downloads

Published

2024-08-05

How to Cite

Rizwanullah, Muzamil Khan, Radhika Bassi, Samah Badr Hamad, Reem Eisa, & Henna Patel. (2024). Chronic Proton Pump Inhibitor Use Leading to Refractory Hypomagnesaemia in a Patient with Rheumatoid Arthritis: A Case Report. Journal of Population Therapeutics and Clinical Pharmacology, 31(8), 160-163. https://doi.org/10.53555/jptcp.v31i8.7281
More Citation Formats

Issue

Section

Articles

How to Cite

Rizwanullah, Muzamil Khan, Radhika Bassi, Samah Badr Hamad, Reem Eisa, & Henna Patel. (2024). Chronic Proton Pump Inhibitor Use Leading to Refractory Hypomagnesaemia in a Patient with Rheumatoid Arthritis: A Case Report. Journal of Population Therapeutics and Clinical Pharmacology, 31(8), 160-163. https://doi.org/10.53555/jptcp.v31i8.7281

Most read articles by the same author(s)